Supporting Information

EGFR Targeted Polymeric Mixed Micelles carrying Gemcitabine for treating Pancreatic Cancer

Goutam Mondal[1], Virender Kumar[1], Surendra K. Shukla[2], Pankaj K. Singh[2] and Ram I. Mahato [1*]



Fig. S1. ^{1}H-NMR of MAL-PEG-PCD



Fig. S2. ^{1}H-NMR of GE11-PEG-PCD



Fig. S3. ^{1}H-NMR of HW12-PEG-PCD



Fig. S4. ^{1}H-NMR of mPEG-b-PCC-g-FC-g-DC



Fig. S5. ^{1}H-NMR of mPEG-b-PCC-g-GEM-g-DC



Fig. S6. EGFR expression in MIA PaCa-2 cells was analyzed by flow cytometry. The profiles represent the values of unstained MIA PaCa-2 cells (red), MIA PaCa-2 cells stained with mouse IgG1 monoclonal - Isotype control antibodies (light blue) and MIA PaCa-2 cells stained with mouse monoclonal antibodies to EGFR (orange).



Fig. S7. Fluorescein cadaverine labeled GE11-linked mixed micelles can enter MIA PaCa-2 cells via EGF receptor. Epifluorescence microscopic images of cells treated with GE11-linked mixed micelles (10% w/w) (A), GE11-linked mixed micelles (20% w/w) (B), GE11-linked mixed micelles (30% w/w) (C), Unmodified micelles (D), HW12-linked mixed micelles (30% w/w) (E) respectively. MIA PaCa-2 cells were pre-incubated with GE11 peptide and then treated with GE11-linked mixed micelles (30% w/w) (F). Scale bar, 100 µM.



Fig. S8. Analysis of major organs (liver, heart and kidney) was performed for hematoxylin and eosin (H&E) staining. Scale bar, 200 μM.